Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | December 06, 2022 | December 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date December 06, 2022 · Filed December 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,970 |
Reported balance
After 2022-12-06 transaction · row 1
1 source rowRow 1 · 2022-12-06 · Sale · Disposed 1,023 · Balance 65,970 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,657 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,312 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,563 Underlying: Common Stock · 5,312 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,085 Underlying: Common Stock · 1,563 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,751 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,752 Underlying: Common Stock · 3,751 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 15,327 | $26.47 | $405,662.77 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,862 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.99 to $26.94. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,312 | $9.05 | $48,073.60 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,563 | $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,751 | $6.45 | $24,193.95 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 292 | $27.19 | $7,939.48 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,157 F1 · shares: The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:13 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,697 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001384101-19-000144 · wf-form4_157532119634376.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,303 Underlying: Common Stock · 3,697 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:13 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,697 | $29.36 | $108,534.31 |
DisclosureSEC source: 0001384101-19-000144 · wf-form4_157532119634376.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,449 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.34 to $29.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:13 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,697 | $14.34 | $53,014.98 |
DisclosureSEC source: 0001384101-19-000144 · wf-form4_157532119634376.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 296 | $25.20 | $7,457.99 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,449 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,063 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F8 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 5,313 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,562 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,648 Underlying: Common Stock · 1,562 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,503 Underlying: Common Stock · 3,750 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 292 | $25.09 | $7,326.28 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 F4 · shares: The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,000 | $26.12 | $52,245.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.81 to $26.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 13,031 | $25.20 | $328,411.17 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.81 to $25.80. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,313 | $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,562 | $5.43 | $8,481.66 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $6.45 | $24,187.50 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,640 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 16 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 4,640 shares Expires 2024-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,640 | $25.45 | $118,088.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,640 | $10.45 | $48,488.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 15 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,469 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 7,083 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 14 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,188 Underlying: Common Stock · 7,083 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 13 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,210 Underlying: Common Stock · 1,563 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,253 Underlying: Common Stock · 5,000 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 8,243 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,642 Underlying: Common Stock · 8,243 shares Expires 2024-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 28,257 | $25.38 | $717,094.84 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.12 to $25.94. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 7,083 | $9.05 | $64,101.15 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,563 | $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,000 | $6.45 | $32,250.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,667 | $8.86 | $14,769.62 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 8,243 | $10.45 | $86,139.35 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:28 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000064 · wf-form4_155976652503137.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,332 F1 · shares: The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 17,625 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000030 · wf-form4_155182249111385.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,875 Underlying: Common Stock · 17,625 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 17,625 | $20.24 | $356,708.85 |
DisclosureSEC source: 0001384101-19-000030 · wf-form4_155182249111385.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,624 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $20.00 to $20.77. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 17,625 | $5.98 | $105,397.50 |
DisclosureSEC source: 0001384101-19-000030 · wf-form4_155182249111385.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 12,396 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · derivative · entry 16 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,271 Underlying: Common Stock · 12,396 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,166 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · derivative · entry 15 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 4,166 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 8,749 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · derivative · entry 14 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,253 Underlying: Common Stock · 8,749 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · derivative · entry 13 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 11,667 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2016, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 397 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · derivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,885 Underlying: Common Stock · 397 shares Expires 2024-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is fully vested and fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.